Decades of studies of candidate genes show their complex role in aging-related traits. We focus on apolipoprotein E e2/3/4 polymorphism and ages at onset of cardiovascular diseases (CVD) and cancer in the parental and offspring generations of the Framingham Heart Study participants to gain insights on the role of age and gender across generations in genetic trade-offs. The analyses show that the apolipoprotein E e4 allele carriers live longer lives without cancer than the non-e4 allele carriers in each generation. The role of the e4 allele in onset of CVD is age-and generation-specific, constituting two modes of sexually dimorphic genetic trade-offs. In offspring, the e4 allele confers risk of CVD primarily in women and can protect against cancer primarily in men of the same age. In the parental generation, genetic trade-off is seen in different age groups, with a protective role of the e4 allele against cancer in older men and its detrimental role in CVD in younger women. The puzzling complexity of genetic mechanisms working in different genders, ages, and environments calls for more detail and systemic analyses beyond those adapted in current large-scale genetic association studies.
Introduction
D ecades of studies of candidate genes show that they are not linked to aging-related traits in a straightforward fashion.
1,2 Recent genome-wide association studies (GWAS) provide fundamentally the same conclusion by showing that the traits in late life are likely controlled by a relatively large number of common genetic variants (e.g., Teslovich et al. 3 ), many of which have a tiny effect. 4 The tiny effect of genes can be because they indeed confer small risks or/and they confer large risks, but in a complex fashion. For example, recent studies demonstrated that genes could show antagonistic pleiotropy (postulated by Williams 5 ), when the same gene can be advantageous for fitness phenotypes in early life but become detrimental by conferring risks of diseases in old ages. 2, [6] [7] [8] [9] [10] In general, the same allele can work differently at different ages. 2, [11] [12] [13] [14] [15] The complex role of genes can readily result in underestimation of the effect. 7 Furthermore, the same genes can confer risk for some traits but protect against the others, exhibiting so-called genetic trade-off. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Again, trade-off among endophenotypes can result in a tiny or no overall effect on an upstream phenotype. For example, Kulminski et al. 17 show that the same allele of the apolipoprotein E (APOE) gene can confer risk for cardiovascular disease (CVD) but can protect against cancer that significantly alters estimates for life span. Sexual dimorphism is another important factor complicating the effect of genes on complex aging-related diseases and traits in humans. 29, 30 In this work, we extend the analyses in Kulminski et al. 17 by focusing on data from the Framingham Heart Study original (FHS) and Offspring (FHSO) cohorts to elucidate the potential role of age and gender in trade-off of the APOE e4 allele on risks of premature onset of CVD and cancer (all sites but skin) across two human generations followed for up to 60 years.
Materials and Methods

Study design and population
The study design of the original (FHS) cohort (launched in 1948) and the FHSO cohort (launched 22 years later) has been described previously. [31] [32] [33] [34] [35] In short, the FHS includes N = 5209 respondents aged 28-62 years at baseline who have been followed biannually during about 60 years. The FHSO respondents (N = 5124) aged 5-70 years at baseline were biological descendants (n = 3514), their spouses (n = 1576), and adopted offspring (n = 34) of the FHS participants who have been followed for about 36 years. The FHS/FHSO participants were examined for the onset of CVD and cancer at regular examinations at the FHS clinic and surveillance of hospital admissions, 33, 34 currently through 2008. Biospecimens were mostly collected in the late 1980s and through 1990s from surviving participants. 36, 37 Accordingly, genotyped FHS and FHSO participants represent demographically unbiased samples of aged populations (File S1; Supplementary Data are available at www.liebertonline.com/rej/). The procedure used for the APOE genotyping is described by Lahoz et al. 36 The limited-access data available for this study include information on the APOE e2/3/4 polymorphism for the 1258 FHS and 3924 FHSO participants.
Analysis
Following the results by Kulminski et al., 17 the analyses were focused on the effect of the APOE e4 (risk; e2/4, e3/4, and e4/4) allele contrasted by the non-e4 allele (e2/2, e2/3, and e3/3) genotypes on ages at onset of CVD (diseases of heart and stroke regardless of condition) and cancer (all sites regardless of condition; skin cancer was excluded).
The analyses were conducted using Kaplan-Meier empirical estimator and the Cox proportional hazards regression model. To better address the role of age in onset of diseases, we used age at event (cases) or the end of follow-up (censored individuals) in 2008 (or death) as a time variable. Given the lack of the APOE-related selection bias (see File S1), the analyses were focused on male and female participants of the baseline examinations in each cohort to maximize the sample size. Five cases of CVD and 3 cases of cancer that occurred prior baseline examination of the FHS genotyped participants, as well as 35 cases of CVD and 22 cases of cancer that occurred prior baseline examination of the FHSO genotyped participants, were excluded from the analyses. The Cox regression model was adjusted for age at baseline and sex, when applicable. To better understand potential modulating role of CVD or cancer on risks of premature (i.e., at younger ages) onset of cancer or CVD, we also conducted the analyses with the Cox model adjusted by alternative diseases (e.g., the model for onset of cancer was adjusted by the prevalence of CVD). We used a robust sandwich estimator in the Cox model to account for potential clustering (e.g., familial). 38 Statistical analyses were conducted using SAS (release 9.3, Cary, NC).
Results
Mean ages at baseline and Kaplan-Meier age patterns of onset of cancer or CVD for male and female carriers of the e4 allele and non-carriers of this allele in the FHS and FHSO cohorts are presented in Figs. S1 and S2. Empirical screening of the age patterns of onset of cancer for men and women combined shows that the e4 carriers tend to live longer lives without cancer (see Fig. S1 ) in each cohort. Sex-specific analyses show that this protective effect is more characteristic for men ( Fig. S1 and Fig. 1A,B) .
Empirical age patterns of onset of CVD for men and women combined show antagonistic effects with the changing role of the e4 allele in the onset of CVD over age in the FHS from detrimental in younger ages to protective in older ages. In the FHSO, we observed the detrimental effect of the e4 allele (Fig. S2 ). Sex-specific analyses suggested a leading role of the e4 allele in women ( Fig. S2 and Fig. 1C,D) .
Cox regression analyses show ( Table 1 ) that both men and women carrying the e4 allele can live longer lives without cancer, although the relative risk (RR) is only marginally significant in men in the FHSO (RR = 0.81, p = 0.079). However, given the same type of empirical age patterns in each cohort ( Fig. S1 and Fig. 1A,B) , the data can be safely pooled together to increase sample size. In the pooled sample of the FHS and FHSO cohorts (Table 1) , the estimates of the RRs of onset of cancer become significant for men and women combined (RR = 0.87, p = 0.046) and marginally significant for men (RR = 0.82, p = 0.055).
Empirical analyses ( Fig. S1 and Fig. 1A ,B) suggest, however, that the protective effect of the e4 allele is disproportionally shifted to onsets in older ages. Accordingly, the Cox regression model with proportional hazards likely provides underpowered estimates in this case. Note that conventional analyses of interactions with age at baseline do not address this problem. When we focus on onsets in older ages (representatively, being older than 65 years at cancer onset for cases or the end of follow up in 2008 for censored individuals; the estimates are robust to the choice of cutoff), we have considerably more compelling estimates (Table 1) in terms of the effect size and significance, e.g., RR = 0.78, p = 6.7 · 10 -3 for men and women combined. Analysis of the RR for onset of CVD without controlling for age specific in the FHS generation shows no significant effect in the sample of men and women combined and for each sex (Table 2 , all ages). The situations for men and women are, however, qualitatively different. Empirical analysis indeed suggests that the e4 allele confers at most a tiny effect in men (Fig. S2C) . This is clearly not the case in women for whom the lack of significant effect is because of complex modalities of gene action (Fig. 1C) . To address the role of the observed disproportionality, we defined more homogeneous groups in the FHS as: ''Younger,'' being 75 years and younger at onset of CVD for cases or the end of follow-up in 2008 (or death) for censored individuals, and ''older,'' being older than 75 years at onset of CVD for cases or the end of follow-up in 2008 (or death) for censored individuals.
The analyses of the ''younger'' group (Table 2) show a highly significant detrimental effect of the e4 allele in the sample of men and women combined (RR = 1.49, p = 7.5 · 10 ). Younger men can also be at higher risk of premature onset of CVD, although the effect is much smaller than in women and it is not significant. The analyses of the ''older'' group show significant protective effect of the e4 allele in women (RR = 0.69, p = 0.025) and marginally significant in men and women combined ( Table 2, FHS) . No effect is, however, seen in men.
In the FHSO cohort, the e4 allele confer risks of premature onset of CVD in men and women combined (RR = 1.22, p = 9.0 · 10
) with a leading role in women (Table 2, FHSO). The effect becomes stronger in older women, defined as being older than 65 years at onset of CVD for cases or the end of follow-up in 2008 (or death) for censored individuals (Table 2) . Importantly, given the complex role of genes in the etiology of traits with well-pronounced post-reproductive manifestation, increasing the sample size (by combining the FHS and the FHSO in this case) can readily result in no effect, just because extending sample can scale the heterogeneity in parallel (e.g., RR = 1.08, p = 0.201 for men and women combined; see Table 2 ).
Connection of the same allele with CVD and cancer raises the question of whether CVD and cancer can be developed in the same e4 carriers or not. To address this problem, we evaluated the confounding role of alternative diseases. The analyses show at most a minor role of CVD as a confounding 
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factor in the models for onset of cancer (see Table S1 ) and of cancer in the models for onset of CVD (see Table S2 ).
Discussion
Extension of the analyses of genetic trade-off in the effect of the e4 allele on risks of premature onset of cancer and CVD presented in Kulminski et al. 17 for the FHS original cohort helps to better characterize the puzzling sensitivity of this phenomenon to gender, ages, and generations. The analyses suggest that the e4 allele can be protective against cancer, with a more pronounced effect in men. This protective effect is more characteristic for cancers at older ages and it holds in the parental and offspring generations of the FHS participants.
Unlike cancer, the effect of the e4 allele on ages at onset of CVD is more pronounced in women. The analyses suggest that the role of this allele in the etiology of CVD can be sensitive to age and generations. In the parental generation of the FHS participants, we observed an antagonistic action of the e4 allele on onset of CVD in women across ages: The e4 allele can confer risks of developing CVD in younger women but protect against CVD in older women. In the offspring generation, the e4 allele can confer risks of developing CVD primarily in older women. Antagonistic action of the same allele at different ages is an important phenomenon that deserves more detailed analyses. 39 Genetic trade-off is at most barely confounded by alternative diseases, primarily because of strong sexual dimorphism.
Thus, our analyses suggest two modes of sexually dimorphic genetic trade-offs. One mode is observed in the FHSO generation when the e4 allele confers risk of premature onset of CVD primarily in women and this allele can protect against cancer primarily in men of the same age. The other mode is pronounced in the FHS generation when genetic trade-off is seen in different age groups with a protective role of the e4 allele against cancer in older men and its detrimental role in CVD in younger women.
In relation to CVD, sexual dimorphism of the APOE gene is widely discussed in literature. For example, studies demonstrate significant heterogeneity in the effect of the e4 allele on coronary heart disease (CHD). Some studies document a more pronounced role of this allele in women, 40 particularly in high-risk women defined by conventional risk factors. 41 Other studies document a more substantial effect of this allele on CHD in men. 42, 43 Sexual dimorphism of the APOE gene is typically attributed to differential hormonal and insulin regulation in men and women. 40 In relation to cancer, given that the mechanism of the protective effect of the e4 allele is unclear and that this effect is largely attributed to non-prostate and non-breast cancer sites, 17, 44 the mechanism of sexual dimorphism appears to be unclear as well. However, given that the protective effect of the e4 allele on cancer is more pronounced at older ages, this effect may, in part, be linked to the effect of the e4 allele on Alzheimer disease (AD). Indeed, the APOE e4 allele is well known to increase the risk of AD, whereas the risk of cancer is significantly smaller among AD patients, as has been recently shown. 22, 45, 46 One potential biological mechanism linking smaller cancer risk in AD patients carrying the e4 allele could be related to inflammation. For example, carriers of the e4 allele have been shown to have lower Creactive protein (CRP) levels, 47 whereas the lower CRP levels have been shown to be associated with reduced overall cancer risk and better prognosis in a number of studies. 48, 49 Differential effects of genes on various phenotypes with well-pronounced post-reproductive manifestation at different ages have been extensively documented in candidate gene studies. [11] [12] [13] [14] [15] 40 Qualitative similarity of the effect of the e4 allele on onset of cancer across generations and dissimilarity across generations in the case of CVD support the hypothesis on the qualitative difference in the mechanisms underlying connection of the e4 allele with CVD and cancer. 17 Given that the APOE gene is directly associated with diet and lifestyle 50, 51 and that these exposures experience dramatic changes across generations, [52] [53] [54] [55] we can hypothesize that in the case of CVD the mechanism is sensitive to modern environment, whereas in the case of cancer this is unlikely to be the case.
Our study also provides explicit evidence that the agingrelated processes in different generations (which are proxies for changing environment) can crucially impact strength and significance of genetic effects on traits in late life. These results contribute to ongoing discussion about a major problem in current GWAS that have failed to explain the proportion of genetic variance contributing to complex phenotypes. 56 This study strongly supports the view that the so-called problem of missing heritability ''is overblown, and the focus on hits that are significant genome-wide is distracting attention from more general concerns over the ability of GWAS to fully describe the architecture of phenotypic variation'' shaping genetic effects. 56, 57 Our results also support the view that ''increasing the size of human disease cohorts is likely only to scale the heterogeneity in parallel'' 58 with nonobvious chances to gain more insights.
Overall, gender-, age-, and generation-specific genetic trade-off of the same e4 allele on seemingly unrelated diseases explicitly demonstrates the puzzling complexity of genetic mechanisms working in different ages, genders, and environments. Current GWAS strategies that are largely adapted to find universal genes working in different settings have to be revisited to reflect the real complexity of gene action on traits with well-pronounced post-reproductive manifestation.
